These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19574794)

  • 1. Modified posterior pelvic exenteration for ovarian cancer.
    Houvenaeghel G; Gutowski M; Buttarelli M; Cuisenier J; Narducci F; Dalle C; Ferron G; Morice P; Meeus P; Stockle E; Bannier M; Lambaudie E; Rouanet P; Fraisse J; Leblanc E; Dauplat J; Querleu D; Martel P; Castaigne D
    Int J Gynecol Cancer; 2009 Jul; 19(5):968-73. PubMed ID: 19574794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases.
    Minar L; Felsinger M; Rovny I; Zlamal F; Bienertova-Vasku J; Jandakova E
    Acta Obstet Gynecol Scand; 2017 Sep; 96(9):1136-1143. PubMed ID: 28585317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
    Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
    Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].
    Emin L; Meeus P; Beurrier F; Ferraioli D; Carrabin N; Ray-Coquard I; Treilleux I; Chopin N
    Gynecol Obstet Fertil; 2015 May; 43(5):342-7. PubMed ID: 25899113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the influence of infection on overall survival rates, following modified posterior pelvic exenteration for advanced ovarian cancer.
    Szymankiewicz M; Dziobek K; Sznajdorwska M; Wicherek L; Dutsch-Wicherek M
    Ginekol Pol; 2018; 89(11):618-626. PubMed ID: 30508214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome.
    Berretta R; Marchesi F; Volpi L; Ricotta G; Monica M; Sozzi G; Di Serio M; Mautone D
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):346-50. PubMed ID: 27343313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
    Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
    Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
    Buttarelli M; Houvenaeghel G; Lelièvre L; Jacquemier J; Guiramand J; Delpero JR
    Ann Chir; 2006 Oct; 131(8):431-6. PubMed ID: 16707093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified posterior exenteration for ovarian cancer.
    Eisenkop SM; Nalick RH; Teng NN
    Obstet Gynecol; 1991 Nov; 78(5 Pt 1):879-85. PubMed ID: 1923216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. En bloc pelvic peritoneal resection of the intraperitoneal pelvic viscera in patients with advanced epithelial ovarian cancer.
    Sainz de la Cuesta R; Goodman A; Halverson SS
    Cancer J Sci Am; 1996; 2(3):152-7. PubMed ID: 9166515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration.
    Kato K; Nishikimi K; Tate S; Kiyokawa T; Shozu M
    World J Surg Oncol; 2015 Jul; 13():230. PubMed ID: 26228239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?: a single-center review of patients with extraluminal pelvic recurrence for rectal cancer from March 2004 to November 2010.
    Ghouti L; Pereira P; Filleron T; Humeau M; Guimbaud R; Selves J; Carrere N
    Am J Surg; 2015 Feb; 209(2):352-62. PubMed ID: 25524284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal complications after pelvic exenterations in gynecologic oncology.
    Forner DM; Lampe B
    Int J Gynecol Cancer; 2009 Jul; 19(5):958-62. PubMed ID: 19574792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Intra-abdominal/Pelvic Inflammation After Radical Surgery for Locally Recurrent Rectal Cancer.
    Tanaka M; Kanemitsu Y; Shida D; Ochiai H; Tsukamoto S; Nagino M; Moriya Y
    Dis Colon Rectum; 2017 Aug; 60(8):827-836. PubMed ID: 28682968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.